Project Grant R43CA291296
Award Date
8/1/24
Completion Date
7/31/26
Dollars Obligated
$800K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Illinois, USA
Similar Awards
This $1,398,552 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports Avantgen Inc., a San Diego-based biotechnology company, in conducting preliminary IND-enabling studies for a novel antibody therapy targeting the Jagged-1 pathway in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). The key products and services to be delivered under this grant include cell line development, early chemistry and manufacturing controls (CMC)...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) provides $792,367 to Nanopharmaceuticals LLC to develop a novel dual-targeting ligand, NP855, for the treatment of high-risk neuroblastoma. The key products and services to be delivered under this grant include: Scaled-up manufacturing and analytical evaluation of the NP855 drug substance to enable formulation of the drug product. In vitro and in vivo studies to confirm the efficacy of the...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $768,437 to the Sanford Burnham Prebys Medical Discovery Institute to conduct research aimed at identifying chemical compounds that inhibit the chromatin reader SGF29, which regulates the transcription of oncogenes in acute myeloid leukemia (AML). The research project will implement high-throughput screening assays developed by the institute to screen chemical libraries and identify...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $435,773 to the University of Maryland, Baltimore to develop an engineered prodrug treatment for inhibiting cancer growth and metastasis, particularly for ovarian, lung, and colon cancers. The research aims to leverage tumor-associated hyperactive membrane-anchored serine proteases on the surface of malignant tumor cells to selectively deliver potent cytotoxins and enhance sensitivity...
This federal Project Grant award of $513,859, provided by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research), supports research to develop a novel adoptive cellular therapy platform using hematopoietic stem cells (HSCs) engineered with chimeric antigen receptor (CAR) technology. The goal is to generate a continuously renewing population of CAR-expressing natural killer (NK) cells that can provide long-term, safe, and efficacious anti-cancer immunity. The research aims to...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $1,568,070.00 to Shasqi Inc., a Hispanic American-owned biotechnology company in San Francisco, CA, to develop innovative drug delivery technologies that enhance therapeutic efficacy while minimizing systemic toxicity. The key products and services to be delivered under this award include characterizing and testing a novel HER2-targeted activating agent conjugated with...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $667,118 to The Regents of the University of California, San Francisco (UCSF) to conduct research aimed at identifying and disabling new pathways for macromolecular recycling in pancreatic cancer. The key products and services to be delivered under this 5-year award include: Exploring the role of the lysosomal hydrolase PLBD1 as an aminopeptidase that removes branched-chain amino acids...
This federal Project Grant award in the amount of $362,741, provided by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research), supports the development and evaluation of an ultra-small epigenetic-regulating nanocarrier system for enhanced synthetic lethal cancer therapy. The key objectives are to: 1) optimize a nanocarrier formulation that can effectively deliver the PARP inhibitor BMN673 and the DNA methylation inhibitor 5-azacytidine to tumors; 2) assess the in vivo...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 Cancer Biology Research) to the Foundation For Applied Molecular Evolution, Inc. provides $215,564 to develop new molecular reagents called "AegisBody" and "AegisCleavers" for cancer research. These novel reagents can bind to and covalently cleave target proteins, like the cancer-relevant PD-L1 protein, unlike traditional antibodies. The goal is to create these more stable and cost-effective...
This federal Project Grant award for $716,314.00 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to develop novel therapeutics targeting FGFR2 alterations in gastroesophageal adenocarcinoma (GEA). The key products and services to be delivered include: Utilizing novel immune-competent mouse models of FGFR2-altered GEA to develop and test highly efficacious FGFR2 biparatopic antibodies (BIPABs) and FGFR2-targeted antibody-drug conjugates (ADCs), alone or in...